Literature DB >> 24189056

Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.

Simone Carradori1, Celeste De Monte, Melissa D'Ascenzio, Daniela Secci, Gulsah Celik, Mariangela Ceruso, Daniela Vullo, Andrea Scozzafava, Claudiu T Supuran.   

Abstract

Salen and tetrahydrosalen derivatives possess metal-chelating properties and have been used as ligands in organic synthesis and as scaffolds for developing therapeutic agents. Fourteen such compounds were synthesized in order to explore their ability to inhibit the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). Human (h) isoforms hCA I, hCA II, hCA IX and hCA XII were included in the investigation. Several aliphatic and aromatic spacers were introduced between the two chelating groups from salen/tetrahydrosalen in order to explore a diverse chemical space for designing CA inhibitors, which incorporate both phenol and polyamine fragments in their molecule. Some of these compounds showed CA inhibitory activity in the low micromolar-nanomolar range and a pronounced selectivity for inhibiting an isoform over-expressed in hypoxic tumors, hCA XII, over hCA I, II and IX.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbonic anhydrase inhibitor; Phenol; Polyamine; Salen; Tetrahydrosalen; Tumor over-expressed CA XII

Mesh:

Substances:

Year:  2013        PMID: 24189056     DOI: 10.1016/j.bmcl.2013.10.026

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Metabolic Effect of Estrogen Receptor Agonists on Breast Cancer Cells in the Presence or Absence of Carbonic Anhydrase Inhibitors.

Authors:  Anissa Belkaid; Miroslava Čuperlović-Culf; Mohamed Touaibia; Rodney J Ouellette; Marc E Surette
Journal:  Metabolites       Date:  2016-05-26

Review 2.  Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.

Authors:  Simone Carradori; Adriano Mollica; Celeste De Monte; Arianna Ganese; Claudiu T Supuran
Journal:  Molecules       Date:  2015-03-31       Impact factor: 4.411

3.  Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms.

Authors:  Melissa D'Ascenzio; Paolo Guglielmi; Simone Carradori; Daniela Secci; Rosalba Florio; Adriano Mollica; Mariangela Ceruso; Atilla Akdemir; Anatoly P Sobolev; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-26       Impact factor: 5.051

4.  Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents.

Authors:  Serena Veschi; Simone Carradori; Laura De Lellis; Rosalba Florio; Davide Brocco; Daniela Secci; Paolo Guglielmi; Mattia Spano; Anatoly P Sobolev; Alessandro Cama
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.

Authors:  Dovile Stravinskiene; Aiste Sliziene; Lina Baranauskiene; Vilma Petrikaite; Aurelija Zvirbliene
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

6.  Benzenesulfonamides with different rigidity-conferring linkers as carbonic anhydrase inhibitors: an insight into the antiproliferative effect on glioblastoma, pancreatic, and breast cancer cells.

Authors:  Francesco Liguori; Simone Carradori; Roberto Ronca; Sara Rezzola; Serena Filiberti; Fabrizio Carta; Marta Turati; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

7.  Synthesis, characterisation, biological evaluation and in silico studies of sulphonamide Schiff bases.

Authors:  Mustafa Durgun; Cüneyt Türkeş; Mesut Işık; Yeliz Demir; Ali Saklı; Ali Kuru; Abdussamat Güzel; Şükrü Beydemir; Suleyman Akocak; Sameh M Osman; Zeid AlOthman; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.